Helium Advisors’s AbbVie ABBV Stock Holding History

Helium Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$308K	Buy	1,176 +8	+0.7%	+$2.05K	0.27%	81
2026 Q2	$294K	Buy	1,168 +3	+0.3%	+$645	0.24%	84
2026 Q1	$253K	Sell	1,165 -5	-0.4%	-$1.11K	0.24%	82
2025 Q4	$267K	Buy	1,170 +26	+2%	+$5.92K	0.27%	68
2025 Q3	$265K	Sell	1,144 -849	-43%	-$173K	0.22%	70
2025 Q2	$370K	Buy	1,993 +323	+19%	+$60K	0.23%	69
2025 Q1	$350K	Buy	1,670 +7	+0.4%	+$1.36K	0.25%	61
2024 Q4	$295K	Buy	+1,663	New	+$306K	0.23%	67

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Helium Advisors's ABBV Position: Q3 2026 in Review

Helium Advisors increased its AbbVie (ABBV) stake by 0.68% in Q3 2026, buying an estimated $2.05K and bringing the position to 1,176 shares worth $308K. The position accounts for 0.27% of the portfolio, ranked #81.

Helium Advisors first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $370K in Q2 2025. 1,436 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Helium Advisors held 1,176 shares of AbbVie worth $308K as of Q3 2026.
Helium Advisors bought 8 AbbVie shares in Q3 2026, an estimated $2.05K.
AbbVie made up 0.27% of Helium Advisors's portfolio in Q3 2026, its #81 holding.
Helium Advisors first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
Helium Advisors's AbbVie position peaked at $370K in Q2 2025.
1,436 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Helium Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.